Summary The presence of human chorionic gonadotropin in large bowel cancers was studied immunohistochemically using an immunoperoxidase technique. HCG-positive tumour cells were present in 42 of 194 adenocarcinomas examined (22.0% of colon cancer and 21.2% of rectal cancers). On histological grading, the hCG-positive rate tended to rise as the degree of differentiation decreased. HCG was detected more frequently in cancers invading the total bowel wall (27%) than in those invading the partial wall (17.1%). Lymph node, liver or peritoneal metastases were present more frequently in hCG-positive tumours than in hCG-negative tumours. Furthermore, there was an intimate correlation between the presence of hCG-positive tumour cells and CEA doubling times in nine cases with untreated liver metastasis. The survival rate for patients with tissue hCG-positive cells was lower than for those with hCG-negative tumours. Thus, the presence of tissue hCG in colorectal cancers may be a biological marker of prognostic significance. 
Some patients with gastrointestinal cancer have been reported to have high serum concentrations of human chorionic gonadotropin (hCG). This finding suggests that there may be tumour cells able to produce hCG, a hormone normally secreted from the placental syncytiotrophoblast. Several reports have shown that the production of hCG by tumour cells is associated with a more aggressive behaviour in gastric and breast cancers (Tormery et al., 1977; Walker, 1978) . The presence of hCG in cancer tissues has been demonstrated in some patients with colorectal cancer by the immunohistochemical method. According to this report, the presence of hCG-positive cells was associated with greater local invasion and the presence of lymph node and liver metastases (Campo et al., 1987) . We have, therefore, studied the incidence of hCG in colorectal cancers and correlated its presence with a variety of clinicopathological parameters.
Materials and methods
We investigated tumour materials from 194 Figure 3 The survival curves of patients undergoing palliative resection (Kaplan-Meier method).
carcinoma, the 5-year survival rate for this group being 53% (Figure 2) . The difference between these two groups was statistically significant (P<0.01). Among patients who underwent palliative resection, the 1-year survival was 53% and the 2-year survival 40% in hCG-negative patients. On the other hand, the 1-year survival was 28% for 20 hCGpositive patients, with no survivors at 2 years ( Figure 3 ).
Discussion
It is now well established that gastrointestinal tumours are associated with a high incidence of hCG production (Braunstein et al., 1973; Goldstein et al., 1974; Ito & Tahara, 1983 (Pierce & Parsons, 1981 ). Fukayama et al. (1987 reported the distribution of hCG subunits to be unbalanced, and the subunits may therefore be expressed through independent mechanisms. They indicated that P-hCG may be expressed through epitheliomesenchymal interactions in carcinomas. Ito & Tahara (1983) argued that there was no difference in the frequency of hCG activity in gastric cancer between early and advanced cancers. In our study, hCG- It has been said that hCG-producing carcinomas carry a poor prognosis and show a high grade of malignancy. Tormey et al. (1977) observed that in breast cancer patients with high serum levels of hCG the response chemotherapy was poor, and remissions were of short duration. It has been reported that the incidence of lymph node metastases is high in breast cancers with hCG-positive tumour cells (Walker, 1978) . Ito & Tahara (1983) reported that the rate of metastasis was high and prognosis was poor in cases of hCG-producing gastric cancer. It has been claimed that hCG-positive large bowel cancers show severe local invasion and high rates of lymph node metastasis (Campo et al., 1987) . In our study, the presence of hCG-positive tumour cells was associated with aggressive local invasion and the presence of metatases. In addition, prognosis was poor in colorectal cancer patients with hCG-immunoreactive cells. All the patients who underwent palliative resection of hCGpositive large bowel cancer died within 2 years of the operation. On the other hand, a 2-year survival rate of 40% was seen in patients with hCG-negative cancer, and some of them are alive nearly 4 years after operation. Among the patients who underwent curative resection, the 5-year survival rate was also significantly lower for hCG-positive than for hCG-negative patients. The results suggest that hCGpositive cancers may carry a poor prognosis and indicate a higher grade of malignancy. There was a close correlation between survival and CEA doubling times for untreated liver metastasis. CEA doubling line has been claimed to be a good index of tumour growth rate (Stabb et al., 1982) . In our study, we found that the CEA doubling times in hCG-positive large bowel cancers were significantly shorter than those in hCG-negative cancers, suggesting that hCG-positive carcinomas have higher proliferative activity and higher growth rates.
Why hCG-producing cancers are of high malignancy grade and carry a poor prognosis is a very interesting question. Several studies have indicated that hCG changes the cellmediated and humoral immune response to the stimulus of cancer antigens (Contractor & Davies, 1973; Fabris et al., 1977; Strelkauskas et al., 1975) . McManus et al. (1976) suggested that the presence of hCG on the tumour surface would suppress the action of the patient's T-cells, thereby favouring high proliferative activity and local invasions. It is, however, difficult to support the theory that there are individual variations in the ability of cells to produce hCG, and thus that a small amount of hCG changes immunological competence. In our study, we have confirmed that prognosis is poor in hCG-producing colorectal cancer. We conclude that the presence of hCG-positive tumour cells reflects the potential malignant behaviour of colorectal cancers.
